PMID- 21948650
OWN - NLM
STAT- MEDLINE
DCOM- 20120426
LR  - 20211020
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 16
IP  - 10
DP  - 2011
TI  - Time to deterioration in quality of life score as a modality of longitudinal 
      analysis in patients with breast cancer.
PG  - 1458-68
LID - 10.1634/theoncologist.2011-0085 [doi]
AB  - PURPOSE: This prospective multicenter study explored different definitions of 
      time to deterioration (TTD) in quality of life (QoL) scores, according to 
      different cutoffs of the minimal clinically important difference (MCID) as a 
      modality for longitudinal QoL assessment in breast cancer patients. METHODS: QoL 
      was assessed using the European Organization for Research and Treatment of Cancer 
      Quality of Life Questionnaire C30 and BR-23 before surgery, after surgery, and 6 
      and 12 months later. The global health score, arm symptoms score (BRAS), and 
      breast symptoms score were analyzed. For a given baseline score, QoL was 
      considered to have deteriorated if this score decreased by >/=5 points at any time 
      point after baseline. Analyses were repeated using an MCID of 10 points and 
      taking the score after surgery as the reference score (to explore the occurrence 
      of response shift). TTD was calculated using the Kaplan-Meier method and Cox 
      regression was used to identify independent factors associated with TTD. RESULTS: 
      Two hundred thirty-five patients underwent axillary lymph node dissection (ALND), 
      222 underwent sentinel lymph node biopsy (SLNB), and 61 underwent SLNB plus ALND. 
      Patients who underwent SLNB had a significantly longer TTD for the BRAS dimension 
      than those who underwent ALND. Cox multivariate analyses showed that treatment 
      using SLNB and age >59 years were independently associated with longer TTD for 
      the BRAS, whereas surgery elsewhere than at the Centre Georges Francois Leclerc 
      was associated with a shorter TTD. CONCLUSION: Exploration of different 
      definitions of TTD in QoL provides meaningful longitudinal QoL results for 
      clinicians.
FAU - Hamidou, Zeinab
AU  - Hamidou Z
AD  - Unite de Biostatistiques et d'Epidemiologie, Centre Georges Franc ois Leclerc, 
      Dijon, France.
FAU - Dabakuyo, Tienhan S
AU  - Dabakuyo TS
FAU - Mercier, Mariette
AU  - Mercier M
FAU - Fraisse, Jean
AU  - Fraisse J
FAU - Causeret, Sylvain
AU  - Causeret S
FAU - Tixier, Herve
AU  - Tixier H
FAU - Padeano, Marie-Martine
AU  - Padeano MM
FAU - Loustalot, Catherine
AU  - Loustalot C
FAU - Cuisenier, Jean
AU  - Cuisenier J
FAU - Sauzedde, Jean-Marc
AU  - Sauzedde JM
FAU - Smail, Marc
AU  - Smail M
FAU - Combier, Jean-Philibert
AU  - Combier JP
FAU - Chevillote, Patrick
AU  - Chevillote P
FAU - Rosburger, Christian
AU  - Rosburger C
FAU - Arveux, Patrick
AU  - Arveux P
FAU - Bonnetain, Franck
AU  - Bonnetain F
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110923
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*pathology/surgery
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Lymph Node Excision
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Sentinel Lymph Node Biopsy
PMC - PMC3228064
COIS- Disclosures: Zeinab Hamidou: None; Tienhan S. Dabakuyo: None; Mariette Mercier: 
      None; Jean Fraisse: None; Sylvain Causeret: None; Herve Tixier: None; 
      Marie-Martine Padeano: None; Catherine Loustalot: None; Jean Cuisenier: None; 
      Jean-Marc Sauzedde: None; Marc Smail: None; Jean-Philibert Combier: None; Patrick 
      Chevillote: None; Christian Rosburger: None; Patrick Arveux: None; Franck 
      Bonnetain: None. The content of this article has been reviewed by independent 
      peer reviewers to ensure that it is balanced, objective, and free from commercial 
      bias. No financial relationships relevant to the content of this article have 
      been disclosed by the authors or independent peer reviewers.
EDAT- 2011/09/29 06:00
MHDA- 2012/04/27 06:00
PMCR- 2012/10/01
CRDT- 2011/09/28 06:00
PHST- 2011/09/28 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/04/27 06:00 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - theoncologist.2011-0085 [pii]
AID - 3725806 [pii]
AID - 10.1634/theoncologist.2011-0085 [doi]
PST - ppublish
SO  - Oncologist. 2011;16(10):1458-68. doi: 10.1634/theoncologist.2011-0085. Epub 2011 
      Sep 23.